Sernova Biotherapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Net Income	-12.38	-15.74	-32.19	-39	-24.42	-6.97
Depreciation & Amortization	0.3	0.34	0.54	0.45	0.44	0.27
Stock-Based Compensation	1.98	2.51	1.75	3.9	7.45	0.22
Other Adjustments	0.54	0.25	-0.15	-0.68	-0.84	-0.88
Change in Receivables	0.25	0.18	0.56	0.23	-0.2	-0.09
Changes in Accounts Payable	1.62	1.54	10.59	4.75	3.31	0.46
Changes in Other Operating Activities	0.41	0.02	0.01	0	-0.16	0.14
Operating Cash Flow	-7.13	-10.91	-18.9	-30.34	-14.42	-6.84
Capital Expenditures	-	-	-	-0.1	-0.33	-0.02
Sale of Property, Plant & Equipment	0.02	0.02	-	-	-	-
Purchases of Investments	-	-	-	-18.05	-59	-
Proceeds from Sale of Investments	-	-	11.08	52.97	13	-
Other Investing Activities	-	-	0.04	-0.04	-0.01	-0.21
Investing Cash Flow	0.02	0.02	11.12	34.78	-46.34	-0.23
Long-Term Debt Issued	2.6	4.94	-	-	-	-
Net Long-Term Debt Issued (Repaid)	2.6	4.94	-	-	-	-
Issuance of Common Stock	1.36	0.25	4.98	-	36.51	29.89
Net Common Stock Issued (Repurchased)	1.36	0.25	4.98	-	36.51	29.89
Other Financing Activities	-0.04	-0.05	0.09	0.5	0.15	1.11
Financing Cash Flow	6.47	5.14	5.07	0.5	36.66	31
Net Cash Flow	-0.63	-5.75	-2.71	4.95	-24.1	23.92
Free Cash Flow	-7.13	-10.91	-18.9	-30.44	-14.75	-6.86
Free Cash Flow Per Share	-	-	-0.06	-0.10	-0.05	-0.03
Levered Free Cash Flow	-7.45	-8.91	-21.05	-33.9	-21.17	-6.11
Unlevered Free Cash Flow	-10	-13.2	-20.53	-35.4	-21.5	-6.08

Updated Jan 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.